Effect of cofactors on NAFLD/NASH and MAFLD - a paradigm illustrating the pathomechanics of organ dysfunction

被引:30
作者
Lonardo, Amedeo [1 ]
Singal, Ashwani K. [2 ]
Osna, Natalia [3 ,4 ]
Kharbanda, Kusum K. [3 ,4 ,5 ]
机构
[1] Azienda Osped Univ, Dept Internal Med, I-41126 Modena, Italy
[2] Univ South Dakota, Sanford Sch Med, Vermillion, SD 57105 USA
[3] Vet Affairs Nebraska Western Iowa Hlth Care Syst, Res Serv, Omaha, NE 68105 USA
[4] Univ Nebraska Med Ctr, Dept Internal Med, Omaha, NE 68198 USA
[5] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA
来源
METABOLISM AND TARGET ORGAN DAMAGE | 2022年 / 2卷 / 03期
关键词
Alcohol; diet; HBV; HCV; HIV; infection; immunity; MAFLD; NAFLD; NASH; metabolic syndrome; HCC; maternal obesity; microbiota; personalized medicine; physical activity; sex differences; FATTY LIVER-DISEASE; HUMAN-IMMUNODEFICIENCY-VIRUS; HEPATITIS-C VIRUS; CONFERS SUSCEPTIBILITY; PHYSICAL-ACTIVITY; RISK; FIBROSIS; BIOPSY; COMPLICATIONS; STEATOSIS;
D O I
10.20517/mtod.2022.14
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Primary nonalcoholic fatty liver disease (NAFLD) is bi-directionally associated with the metabolic syndrome and its constitutive features ("factors": impaired glucose disposal, visceral obesity, arterial hypertension, and dyslipidemia). Secondary NAFLD occurs due to endocrinologic disturbances or other cofactors. This nosography tends to be outdated by the novel definition of metabolic associated fatty liver disease (MAFLD). Irrespective of nomenclature, this condition exhibits a remarkable pathogenic heterogeneity with unpredictable clinical outcomes which are heavily influenced by liver histology changes. Genetics and epigenetics, lifestyle habits [including diet and physical (in)activity] and immunity/infection appear to be major cofactors that modulate NAFLD/MAFLD outcomes, including organ dysfunction owing to liver cirrhosis and hepatocellular carcinoma, type 2 diabetes, chronic kidney disease, heart failure, and sarcopenia. The identification of cofactors for organ dysfunction that may help understand disease heterogeneity and reliably support inherently personalized medicine approaches is a research priority, thus paving the way for innovative treatment strategies.
引用
收藏
页数:12
相关论文
共 129 条
[1]   Risks of Light and Moderate Alcohol Use in Fatty Liver Disease: Follow-Up of Population Cohorts [J].
Aberg, Fredrik ;
Puukka, Pauli ;
Salomaa, Veikko ;
Mannisto, Satu ;
Lundqvist, Annamari ;
Valsta, Liisa ;
Perola, Markus ;
Farkkila, Martti ;
Jula, Antti .
HEPATOLOGY, 2020, 71 (03) :835-848
[2]   NAFLD and Infection, a Nuanced Relationship [J].
Adenote, Abimbola ;
Dumic, Igor ;
Madrid, Cristian ;
Barusya, Christopher ;
Nordstrom, Charles W. ;
Rueda Prada, Libardo .
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 2021
[3]   NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations [J].
Adinolfi, Luigi Elio ;
Rinaldi, Luca ;
Guerrera, Barbara ;
Restivo, Luciano ;
Marrone, Aldo ;
Giordano, Mauro ;
Zampino, Rosa .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2016, 17 (06)
[4]   Microbiomics, Metabolomics, Predicted Metagenomics, and Hepatic Steatosis in a Population-Based Study of 1,355 Adults [J].
Alferink, Louise J. M. ;
Radjabzadeh, Djawad ;
Erler, Nicole S. ;
Vojinovic, Dina ;
Medina-Gomez, Carolina ;
Uitterlinden, Andre G. ;
de Knegt, Robert J. ;
Amin, Najaf ;
Ikram, M. Arfan ;
Janssen, Harry L. A. ;
Kiefte-de Jong, Jessica C. ;
Metselaar, Herold J. ;
van Duijn, Cornelia M. ;
Kraaij, Robert ;
Darwish Murad, Sarwa .
HEPATOLOGY, 2021, 73 (03) :968-982
[5]  
Allard Julien, 2019, Adv Pharmacol, V85, P75, DOI 10.1016/bs.apha.2019.01.003
[6]   Nonalcoholic fatty liver disease [J].
Brunt, Elizabeth M. ;
Wong, Vincent W. -S. ;
Nobili, Valerio ;
Day, Christopher P. ;
Sookoian, Silvia ;
Maher, Jacquelyn J. ;
Bugianesi, Elisabetta ;
Sirlin, Claude B. ;
Neuschwander-Tetri, BrentA. ;
Rinella, Mary E. .
NATURE REVIEWS DISEASE PRIMERS, 2015, 1
[7]   Systematic Review: Diagnostic Accuracy of Biomarkers of Alcohol Use in Patients With Liver Disease [J].
Arnts, Janique ;
Vanlerberghe, Benedict T. K. ;
Roozen, Sylvia ;
Crunelle, Cleo L. ;
Masclee, Ad A. M. ;
Olde-Damink, Steven W. M. ;
Heeren, Ron M. A. ;
van Nuijs, Alexander ;
Neels, Hugo ;
Nevens, Frederik ;
Verbeek, Jef .
ALCOHOL-CLINICAL AND EXPERIMENTAL RESEARCH, 2021, 45 (01) :25-37
[8]   Sarcopenia in the setting of nonalcoholic fatty liver [J].
Arrese, Marco ;
Cabello-Verrugio, Claudio ;
Arab, Juan Pablo ;
Barrera, Francisco ;
Baudrand, Rene ;
Guarda, Francisco J. ;
Gul, Iram ;
Cabrera, Daniel .
METABOLISM AND TARGET ORGAN DAMAGE, 2022, 2 (01)
[9]   Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity [J].
Arrese, Marco ;
Arab, Juan P. ;
Barrera, Francisco ;
Kaufmann, Benedikt ;
Valenti, Luca ;
Feldstein, Ariel E. .
SEMINARS IN LIVER DISEASE, 2021, 41 (04) :421-434
[10]   Innate Immunity and Inflammation in NAFLD/NASH [J].
Arrese, Marco ;
Cabrera, Daniel ;
Kalergis, Alexis M. ;
Feldstein, Ariel E. .
DIGESTIVE DISEASES AND SCIENCES, 2016, 61 (05) :1294-1303